Univariate Survival Analysis by the IPI Score, Factors Used to Construct the IPI, B Symptoms, s-CD44 Level, WF Grade, and Gender
| Factor . | N . | 5-yr Survival (%) . | P Value . |
|---|---|---|---|
| IPI score | |||
| 0 | 30 | 90 | <.0001 |
| 1 | 62 | 66 | |
| ≥2 | 91 | 33 | |
| s-LDH | |||
| ≤450 U/L | 129 | 64 | <.0001 |
| >450 U/L | 55 | 27 | |
| WHO performance status | |||
| 0 | 103 | 70 | <.0001 |
| 1 | 59 | 46 | |
| 2-4 | 32 | 12 | |
| Stage | |||
| I | 65 | 69 | .0001 |
| II | 50 | 58 | |
| III | 32 | 40 | |
| IV | 45 | 33 | |
| Age | |||
| ≤60 yr | 104 | 62 | .0002 |
| >60 yr | 90 | 41 | |
| S-CD44, highest tertile | |||
| ≤514 ng/mL | 129 | 62 | .0005 |
| >514 ng/mL | 65 | 38 | |
| No. of extranodal sites | |||
| 0-1 | 172 | 56 | .001 |
| >1 | 20 | 25 | |
| B symptoms | |||
| No | 155 | 58 | .002 |
| Yes | 38 | 32 | |
| S-CD44, median | |||
| ≤440 ng/mL | 97 | 62 | .007 |
| >440 ng/mL | 97 | 44 | |
| WF grade | |||
| Low | 48 | 67 | .02 |
| Intermediate | 90 | 55 | |
| High | 48 | 38 | |
| Gender | |||
| Male | 88 | 56 | .37 |
| Female | 106 | 51 |
| Factor . | N . | 5-yr Survival (%) . | P Value . |
|---|---|---|---|
| IPI score | |||
| 0 | 30 | 90 | <.0001 |
| 1 | 62 | 66 | |
| ≥2 | 91 | 33 | |
| s-LDH | |||
| ≤450 U/L | 129 | 64 | <.0001 |
| >450 U/L | 55 | 27 | |
| WHO performance status | |||
| 0 | 103 | 70 | <.0001 |
| 1 | 59 | 46 | |
| 2-4 | 32 | 12 | |
| Stage | |||
| I | 65 | 69 | .0001 |
| II | 50 | 58 | |
| III | 32 | 40 | |
| IV | 45 | 33 | |
| Age | |||
| ≤60 yr | 104 | 62 | .0002 |
| >60 yr | 90 | 41 | |
| S-CD44, highest tertile | |||
| ≤514 ng/mL | 129 | 62 | .0005 |
| >514 ng/mL | 65 | 38 | |
| No. of extranodal sites | |||
| 0-1 | 172 | 56 | .001 |
| >1 | 20 | 25 | |
| B symptoms | |||
| No | 155 | 58 | .002 |
| Yes | 38 | 32 | |
| S-CD44, median | |||
| ≤440 ng/mL | 97 | 62 | .007 |
| >440 ng/mL | 97 | 44 | |
| WF grade | |||
| Low | 48 | 67 | .02 |
| Intermediate | 90 | 55 | |
| High | 48 | 38 | |
| Gender | |||
| Male | 88 | 56 | .37 |
| Female | 106 | 51 |